Mark Nocerini, Ph.D. has over 25 years’ experience in the biotechnology and pharmaceutical industries. His background includes drug discovery, drug development, and technology evaluation and development. He has interacted extensively with many disciplines on cross-functional teams, including Chemistry, Biology, Molecular Biology, Toxicology, Pharmaceutical R&D, Clinical, Regulatory, and Licensing. His background has included creating and leading new organizations, including strategic and tactical plan development. In his leadership role in the DMPK group at Pfizer, therapeutic area responsibility included cardiovascular and metabolic diseases, oncology, inflammation, gastrointestinal diseases, allergy and respiratory diseases, infectious diseases, and immunology.
While at Abgenix, he built and directed a group with responsibility for developing and implementing high throughput/content screens for potential antibody candidate assessment, and target and candidate evaluation using microarray and other expression profiling technologies. More recently at M-Biotech, he spearheaded fundraising and out-licensing efforts for this early-stage medical device company. He has supervised groups of up to 40 scientists. Dr. Nocerini received a B.S. degree in Biology at Gonzaga University and M.S. and Ph.D. degrees from Washington State University in Nutrition, both with Metabolism and Toxicology emphasis. He is author of 24 peer-reviewed research publications, numerous abstracts, and has contributed to 4 invited manuscripts.